Home/Pipeline/AIR Platform

AIR Platform

Solid Tumors

PreclinicalActive

Key Facts

Indication

Solid Tumors

Phase

Preclinical

Status

Active

Company

VerImmune

About VerImmune

VerImmune is pioneering a novel immunotherapy approach that leverages the body's existing immune memory against common pathogens to fight cancer. Its Anti-Tumor Immune Redirection (AIR) platform engineers bispecific molecules that bridge pathogen-specific T cells to tumor cells, aiming to activate a potent and targeted anti-cancer response. As a private, preclinical-stage biotech, the company's success hinges on validating its unique mechanism in the clinic and navigating the complex competitive landscape of immuno-oncology. If successful, AIR could offer a new therapeutic paradigm with the potential for strong efficacy and a favorable safety profile.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed